Chunlan Pu

发表

Design, synthesis and biological evaluation of indole derivatives as Vif inhibitors.

Yong-tang Zheng, Rong-Hua Luo, Rui Li, 2017, Bioorganic & medicinal chemistry letters.

Synthesis and biological evaluation of a novel c-Myc inhibitor against colorectal cancer via blocking c-Myc/Max heterodimerization and disturbing its DNA binding.

Rui Li, Dan Luo, Hongjia Zhang, 2022, European journal of medicinal chemistry.

Discovery of a novel covalent CDK4/6 inhibitor based on palbociclib scaffold.

Xinyu R. Ma, Yuanyuan Liu, Jie Yang, 2021, European journal of medicinal chemistry.

Current strategies for improving limitations of proteolysis targeting chimeras

Rui Li, Zhonghui Feng, Hongjia Zhang, 2022, Chinese Chemical Letters.

Anti-fibrotic effect of extracellular vesicles derived from tea leaves in hepatic stellate cells and liver fibrosis mice

Zhaoyu Zeng, T. Jiang, Yuanbiao Guo, 2022, Frontiers in Nutrition.

Identification of hit compounds for squalene synthase: Three‐dimensional quantitative structure‐activity relationship pharmacophore modeling, virtual screening, molecular docking, binding free energy calculation, and molecular dynamic simulation

J. Shi, Meng Zhou, Rui Li, 2017 .

Synthesis and biological evaluation of novel 2,3-dihydrochromeno[3,4-d]imidazol-4(1H)-one derivatives as potent anticancer cell proliferation and migration agents.

Meng Zhou, Rui Li, Guoyi Yan, 2016, European journal of medicinal chemistry.

Design, Synthesis and Biological Evaluation of 4, 6-Coumarin Derivatives as Anti-Cancer and Apoptosis-Inducing Agents.

Meng Zhou, Rui Li, Guoyi Yan, 2021, Anti-cancer agents in medicinal chemistry.

Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors.

Rui Li, Lifeng Zhao, Jie Yang, 2019, European journal of medicinal chemistry.

Discovery of a PROTAC targeting ALK with in vivo activity.

Jie Yang, Meng Zhou, Rui Li, 2021, European journal of medicinal chemistry.

Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer.

Rui Li, Hongjia Zhang, Xinyu R. Ma, 2022, European journal of medicinal chemistry.

Pharmacophore‐based virtual screening, molecular docking, molecular dynamics simulation, and biological evaluation for the discovery of novel BRD4 inhibitors

Rui Li, Guoyi Yan, Suke Lan, 2018, Chemical biology & drug design.

Assessing the performance of docking scoring function, FEP, MM-GBSA, and QM/MM-GBSA approaches on a series of PLK1 inhibitors.

Jianyou Shi, Rui Li, Guoyi Yan, 2017, MedChemComm.

Discovery of the GSH responsive "Y-PROTACs" targeting ALK and CDK4/6 as a potential treatment for cancer.

Rui Li, Hongjia Zhang, Yuanyuan Liu, 2023, European journal of medicinal chemistry.

Synthesis and biological evaluation of a tumor-selective degrader of PARP1.

Rui Li, Hongjia Zhang, Rui-Cheng Deng, 2022, Bioorganic & medicinal chemistry.

Development of PROTAC degrader probe of CDK4/6 based on DCAF16.

Rui Li, Hongjia Zhang, Qingjia Xu, 2023, Bioorganic chemistry.

Assessing the performance of docking scoring function, FEP, MM-GBSA, and QM/MM-GBSA approaches on a series of PLK1 inhibitors.

Jianyou Shi, Rui Li, Guoyi Yan, 2017, MedChemComm.

Development of PROTAC degrader probe of CDK4/6 based on DCAF16.

Rui Li, Hongjia Zhang, Qingjia Xu, 2023, Bioorganic chemistry.

Synthesis and biological evaluation of 3-(1,3,4-oxadiazol-2-yl)-1,8-naphthyridin-4(1H)-ones as cisplatin sensitizers.

Hao Luo, Rui Li, Guoyi Yan, 2018, MedChemComm.